Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: 75045-07-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
MB2 (2-mercaptomethylbenzimidazole, CAS n° 53988 -10 -6):
Male and female rats were treated orally by gavage with 2-mercaptomethylbenzimidazole at doses of 0 (corn oil), 4, 20 and 100 mg/kg bw for 28 consecutive days. Clinical signs, body weight, food consumption, organ weights, clinical biochemistry and hematological parameters were recorded and a histopathological examination was conducted.
ZMB2 (1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione, zinc salt, CAS n° 61617 -00 -3):
In a combined repeated-dose reproductive/developmental toxicity study, 2-mercaptomethylbenzimidazole, zinc salt was administered orally in the diet to rats (10/sex/dose) at 1000, 2750 or 7500 ppm (ca. 50, 138 or 375 mg/kg bw/d). These dose levels were reduced to 900, 2500 or 6750 ppm (ca. 45, 125 or 338 mg/kg bw/d) on day 29. On study day 33 the high dose level was further reduced to 5500 ppm (ca. 275 mg/kg bw/d). Signs of systemic toxicity, body weight, food consumption, blood chemistry and hematological parameters, organ weights and histopathological examinations were recorded.
No repeated dose studies for inhalation and dermal toxicity are available
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 4 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The materials/methods and results are described in detail und are sufficient for evaluation
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
MB2 (2-mercaptomethylbenzimidazole, CAS n° 53988 -10 -6):
In the 28 day repeated dose study the relative organ weights of lung, liver, kidney, and serum cholesterol and phospholipid significantly increased in male rats treated with MMBIs at doses of 20 and 100 mg/kg bw/d. Male rats administered 100 mg/kg bw/d exhibited a 1.8 fold increase in thyroid weight associated with histopathological changes but not altered serum thyroid hormone levels. Haematology and urine analysis were uneffected. Female rats administered 100 mg/kg bw/d MMBIs exhibited significant increases of liver and kidney but not thyroid weights and serum cholesterol levels.
Reproductive organs of the rats were examined histopathologically. No adverse effects were reported from these organs. Based on these results there are no indications for specific adverse effects on the reproductive organs up to 100 mg/kg bw/day.
The no-observed-effect levels for male and female rats were found to be 4 and 20 mg/kg bw/d, respectively.ZMB2 (1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione, zinc salt, CAS n° 61617 -00 -3):
The administration of the substance to male and female rats at dose levels up to 7500 ppm (adjusted to 6750 ppm and then to 5500 ppm), for a period of up to 47 days, resulted in treatment-related toxic effects upon adults. A No Observed Adverse Effect Level (NOAEL) was not established.
The lowest-observed-adverse-level LOAEL (systemic) was 45 -50 mg/kg bw/day (based on decreased body weight gain).
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
The most reliable study for the determinatin of a NOAEL was used as key study and for classification
Justification for classification or non-classification
The no-observed-effect level (NOEL) of MMBls, under the conditions of the present subacutce toxicity study, was evaluated to be 4 mg/kg, based on the significant increases of relative liver and kidney weights and serum levels of T-CHO (total cholesterol) at doses of 20 mg/kg and above for male rats, and the NOEL for female rats was 20 mg/kg.
MB2 (2-mercaptomethylbenzimidazole, CAS n° 53988 -10 -6):
In the low dose level of the 28 day study effects were obvious, but these effects are regarded as adaptive effects and not as severe effects.At the termination of the 2-wk recovery period, changes in the absolute organ weights were no longer apparent.
ZMB2 (1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione, zinc salt, CAS n° 61617 -00 -3):
In the combined repeated-dose reproductive/developmental toxicity study, the administration of the substance to male and female rats
at dose levels up to 7500 ppm (adjusted to 6750 ppm and then to 5500 ppm ), for a period of up to 47 days, resulted in treatment-related toxic effects upon adults. A No Observed Adverse Effect Level (NOAEL) was not established.The lowest-observed-adverse-level LOAEL (systemic) was 45 -50 mg/kg bw/day (based on decreased body weight gain).
Therefore based on the result of the oral 28 d repeated dose study (increased organ weights) and the combined repeat-dose reproductive/ developmental toxicity study which has similar results as the 28 d repeat dose study a classification as Xn; R48/22 (GHS: STOT Rep. 2; H373) is justified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.